

RESEARCH

Open Access



# High SARS-CoV-2 seroprevalence among street adolescents in Lomé, Togo, 2021

Arnold Junior Sadio<sup>1,2,3</sup>, Valentine Marie Ferré<sup>4,5</sup>, Rodion Yao Konu<sup>1,2,3</sup>, Anoumou Claver Dagnra<sup>6</sup>, Diane Descamps<sup>4,5</sup>, Didier Koumavi Ekouevi<sup>1,2,3\*</sup> and Charlotte Charpentier<sup>4,5</sup>

## Abstract

**Background** There is almost no data on the circulation of SARS-CoV-2 among street adolescents. We conducted a study to document the immunization status of street adolescents in Togo against different variants of SARS-CoV-2.

**Methods** A cross-sectional study was carried out in 2021 in Lomé, the city with the highest number of COVID 19 cases in Togo (60%). Adolescents aged 13- and 19 years old living on the street were eligible for inclusion. A standardized questionnaire was administered face-to-face to adolescents. A sample of blood was taken and aliquots of plasma were transported to the virology laboratory of the *Hôpital Bichat-Claude Bernard (Paris, France)*. SARS-CoV-2 anti-S and anti-N IgG were measured using chemiluminescent microparticle immunoassay. A quantitative miniaturized and parallel-arranged ELISA assay was used to detect IgG antibodies specifically directed against the different SARS-CoV-2 Variants of Concern (VOC).

**Results** A total of 299 street adolescents (5.2% female), median age 15 years, interquartile range (14-17 years), were included in this study. The prevalence of SARS-CoV-2 infection was 63.5% (95%CI: 57.8–69.0). Specific-IgG against the ancestral Wuhan strain was developed by 92.0% of subjects. The proportion of patients being immunized against each VOC was 86.8%, 51.1%, 56.3%, 60.0, and 30.5% for the Alpha, Beta, Gamma, Delta, and Omicron VOCs, respectively.

**Conclusion** This study showed a very high prevalence with approximately 2/3 of Togolese street adolescents having antibodies to SARS-CoV-2 due to a previous infection. These results confirm an under-reporting of COVID-19 cases in Togo, questioning the hypothesis of low virus circulation in Togo and even in Africa.

**Keywords** SARS-CoV-2 seroprevalence, Street adolescents, Togo

\*Correspondence:

Didier Koumavi Ekouevi  
didier.ekouevi@gmail.fr

<sup>1</sup>Faculty of Health Sciences, Department of Public Health, University of Lomé, Center for Training and Research in Public Health, Lomé, Togo

<sup>2</sup>African Center for Research in Epidemiology and Public Health (CARESP), Lomé, Togo

<sup>3</sup>Research Institute for Sustainable Development (IRD), University of Bordeaux, National Institute for Health and Medical Research (INSERM), Bordeaux Population Health Centre, UMR 1219, Bordeaux, France

<sup>4</sup>Paris Cité University and Sorbonne Paris Nord University, IAME, Inserm, Paris F-75018, France

<sup>5</sup>Virology Unit, AP-HP, Hôpital Bichat-Claude Bernard, Paris F-75018, France

<sup>6</sup>Laboratory of Molecular Biology and Immunology, University of Lomé, Lomé, Togo



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

The true magnitude of the SARS-CoV-2 epidemic is unknown in sub-Saharan Africa. According to existing data, only 1.7% of Covid-19 cases have been reported in Africa out of more than 517 million cases worldwide [1]. One way to estimate the true extent of the epidemic is to conduct seroprevalence surveys [2]. The last study conducted in Togo in 2021, in twelve health districts, with the inclusion of more than 7000 people, reported a seroprevalence of 65.5% [3]. These studies are essentially household surveys, which are costly and time-consuming and therefore difficult to repeat over time. Epidemiological surveillance surveys can also be carried out in specific populations, as is the case in France where a study was carried out among homeless people and showed a circulation of the virus among this population after the first epidemic wave [4]. Homeless people are particularly vulnerable to SARS-CoV-2 infection. Indeed, several risk factors for SARS-CoV-2 infection are found in these populations, including promiscuity, multiple residence in often poorly ventilated dwellings, and frequent contact with many people in community support services. In addition, they are at increased risk for severe COVID-19, being exposed to a high prevalence of comorbidities [5–7].

In Africa, there are populations that live in conditions as precarious as the homeless and are just as vulnerable: street adolescents. This is a very mobile population that is often found in city markets, border crossings and roadside pay stations. This population of street adolescents was on the almost excluded of all risk mitigation measures taken by governments. In 2021, we conducted a study among street adolescents to assess the feasibility of HIV self-testing. As this study was conducted in the midst of the COVID-19 pandemic, and considering the lack of epidemiological data in the literature on SARS-CoV-2 infection in this population, we conducted an ancillary study to document the immunization status of street adolescents in Togo against different variants of SARS-CoV-2.

## Methods

### Study design and setting

This study was part of a survey aimed at describing the acceptability and feasibility of HIV self-testing among street adolescents in Lomé (the capital city of Togo). This was a cross-sectional study conducted from June 26th to July 3rd, 2021 after the second wave of pandemics.

Togo is a West African country covering a 56,800 km<sup>2</sup> area with an average density of 145 inhabitants per square kilometer [8]. The population was 8.08 million in 2019, of which 50.2% were women [9]. Most of the population is under 25 years of age (60%), and lives in rural areas (62%) [9]. Togo's health system has a pyramidal structure with

three levels: central, intermediate and peripheral. Each level has administrative and health care delivery components. Lomé is the largest urban center in the country and at the time of the survey, the city alone accounted for more than 60% of reported COVID-19 cases in Togo [10].

### Study population and sample size

All adolescents aged between 13- and 19-years old living in the street were eligible for inclusion following informed consent. After listing all the places where street adolescents gather in Lomé, a team of investigators went to each site accompanied by local NGOs working with the street child population. After explaining the study to the adolescents, those who agreed to participate were asked to sign a consent form if they were over 18 years old. Adolescents under the age of 18 were asked to give their assent to participate in the study, and then a member of the NGO involved in the care of street adolescents was asked to sign a consent form.

### Data collection

A standardized questionnaire was administered face-to-face to adolescents. It included socio-demographic characteristics, sexual practices, and history of HIV testing. Then, a sample of 04 ml of venous blood was taken.

### Laboratory procedures

Aliquots of plasma were taken to the laboratory of molecular biology and immunology of the University of Lomé (Lomé, Togo) and transported frozen to the virology laboratory of the *Hôpital Bichat-Claude Bernard (Paris, France)*, for the search for anti-SARS-CoV-2 antibodies.

SARS-CoV-2 anti-S and anti-N IgG were measured using the automated Abbott SARS-CoV-2 IgG kit (chemiluminescent microparticle immunoassay, CLIA) (Abbott, IL, USA) using the Alinity platform according to the manufacturer's instructions. In addition, the CoViDiag kit (SirYus CoViDiag+, Innobiochips®, Loos, France), a quantitative miniaturized and parallel-arranged ELISA assay [11], was used to detect IgG antibodies specifically directed against the different SARS-CoV-2 Variants Of Concern (VOC) including BA.1 Omicron sublineage with a threshold at 18 BAU/mL. CoViDiag microtitration plates wells are coated with 4 different SARS-CoV-2 antigens and 4 RBD domains from different VOC separately. They are dedicated to bind specific antibodies in the tested samples and therefore deliver different responses in one single assay.

### Case definition

A sample was considered positive if any of the following conditions were met: (i) the presence of anti-protein S antibodies; (ii) the presence of anti-N antibodies; or (iii) a result in the greyzone of the assays. An humoral response

was defined as having a positive titer against the VOC using the COVIDIAG assay.

### Statistical analysis

We performed descriptive statistics, and the results were presented using frequency tabulations and percentages for categorical variables. Quantitative variables were presented as medians with their interquartile range (IQR). Kruskal-Wallis rank sum test or Wilcoxon test were used for comparison when appropriate. Prevalences of SARS-CoV-2 antibodies were estimated with their 95% confidence interval (95%CI).

### Results

A total of 299 street adolescents, median age 15 years, interquartile range (IQR) (14–17 years), of which 5.2% (n=16) were female were included in this study. Among these, 246 out of 299 (82.3%) are of Togolese nationality (Table 1).

Anti-S IgG serology was positive for 190 of the 299 tested samples leading to a prevalence of SARS-CoV-2 infection of 63.5% (CI 95%: 57.8–69.0). Anti-N IgG antibodies, marker of a more recent infection, were positive for 125 samples (41.8%; CI 95%: 36.2–47.6) (Table 1).

VOC-specific anti-S IgG titers were assessed for the 190 samples with positive anti-S IgG. 175/190 (92.0%) subjects developed specific-IgG against the ancestral Wuhan strain. The 8% of subjects showing no anti-S IgG against the ancestral Wuhan strain had anti-S IgG titers  $\leq$  18 BAU/mL, which is the LOQ of the multiplex ELISA assay. The proportion of patients with presence of anti-S

IgG against each VOC was 86.8% (n=165/190), 51.1% (n=97/190), 56.3% (n=107/190), 60.0% (n=114/190), and 30.5% (n=58/190) for the Alpha, Beta, Gamma, Delta and Omicron VOCs, respectively (Fig. 1). The proportion of the population harbouring a humoral response against the ancestral strain and the Alpha VOC were significantly higher than against all other VOCs ( $p < 0.0001$  for Beta, Gamma, Delta and Omicron VOCs).

Among subjects who developed an immunity against one or several VOCs, the median titers were 68 BAU/mL (IQR=28–162), 81 (IQR=34–182), 62 (IQR=26–175), 53 (IQR=24–155) and 33 (IQR=21–54) for the Alpha, Beta, Gamma, Delta and Omicron VOCs, respectively (Fig. 2).


Among participants who showed an humoral response, Anti-S IgG median titers were significantly lower against Delta and Omicron variants compared to the ancestral Wuhan strain ( $p = 0.0003$  and  $p < 0.0001$ , respectively). Regarding a potential humoral response against the Omicron variant not yet encountered by this population at the time of sampling, anti-S1 RBD IgG median titers were significantly lower against this future new VOC at that time compared to all the variants studied ( $p < 0.0001$ ,  $p = 0.0002$  and  $p = 0.0023$  for Alpha, Beta, Gamma and Delta VOCs, respectively) (Fig. 2).

### Discussion


A seroprevalence study was conducted in a Togolese vulnerable population at high risk of infection because of non-compliance with government-mandated barrier measures to mitigate the risk of SARS-CoV-2 infection. A total of 2 out of 3 adolescents had anti-S antibodies

**Table 1** Seroprevalence of SARS-CoV-2 antibodies by sociodemographic characteristics

	N	Anti-S antibody			Anti-N antibody		
		n	%	95%CI	n	%	95%CI
<b>Overall</b>	299	190	63.5	57.8–69.0	125	41.8	36.2–47.6
<b>Age (years)</b>							
<b>Median [IQR]</b>	15	[14–17]					
10–14	105	63	60.0	50.0–69.3	40	38.1	28.9–48.1
15–19	194	127	65.5	58.3–72.0	85	43.8	36.8–51.1
<b>Sex</b>							
Female	16	9	56.2	30.6–79.2	4	25.0	8.3–52.6
Male	283	181	64.0	58.0–69.5	121	42.8	36.9–48.8
<b>Nationality</b>							
Other	53	36	67.9	53.6–79.7	22	41.5	28.4–55.8
Togolese	246	154	62.6	56.2–68.6	103	41.9	35.7–48.3
<b>Education level</b>							
No academic	23	13	56.5	34.9–76.1	13	56.5	34.9–76.1
Primary	121	75	62.0	52.6–70.5	40	33.1	24.9–42.3
Secondary	121	81	66.9	57.7–75.1	55	45.5	36.5–54.7
Superior	34	21	61.8	43.6–77.3	17	50.0	34.1–65.9
<b>HIV serology</b>							
Negative	296	189	63.9	58.1–69.3	125	42.2	36.6–48.1
Positive	3	1	33.3	1.8–87.5	0	0.0	0.0–69.0



**Fig. 1** Proportion of population harbouring humoral response against the SARS-CoV-2 Spike RBD of the different strains studied among the participants tested positive for anti-S SARS-CoV-2 IgG in ELISA (n = 190)



**Fig. 2** Titers of IgG antibodies anti-SARS-CoV-2 Spike RBD of different variants using the COVIDIAG multiplex ELISA assay measured in the population harbouring a positive SARS-CoV-2 anti-S IgG serology (n = 190)

demonstrating significant virus circulation as of June 2021. The results observed are comparable to those observed in the Togolese general population in April 2021 (65.5%) [3], and prove an under-reporting of SARS-CoV-2 infection in the country. Indeed, as of July 30, 2021, less than 40,000 cases (0.5% of the Togolese population) of SARS-CoV-2 infections were officially reported in Togo [10].

This study, which is the first seroprevalence study among the street’s adolescents, also documented recent infections with the identification of Anti-N IgG antibodies, which is not the case in the majority of SARS-CoV-2 seroprevalence surveys that document only antibodies targeting the Spike protein. The results show that 42% of street adolescents had a recent SARS-CoV-2 infection. Differential reactivity of S- and N-specific antibodies can be used to help differentiate prior infection

from vaccination in serological studies, particularly for vaccines that produce antibodies only to the S protein [12–14]. The presence of isolated anti-S antibodies can also result from a past COVID-19 infection, after the disappearance of the anti-N antibodies, known to decrease more rapidly than the anti-S antibodies [15, 16]. However, for the present study, given the start date of vaccination in Togo and the target chosen at the beginning, it can be said that surveyed street adolescents were not vaccinated. Indeed, vaccination in Togo began on March 10, 2021, and was limited to health professionals and people aged 20 years and older at the end of the study.

Regarding the research of SARS-CoV-2 variants, this is not systematically carried out in Togo. It is only performed during epidemic peaks for surveillance purposes and to adjust the response measures against the pandemic. So, no naso-pharyngeal samples were available in this study, preventing to have a description of the circulating SARS-CoV-2 variants in this adolescent's population. As of August 4, 2021, official genotyping data from samples collected in Togo reported 90% of Delta and 1.3% of Eta variant [17]. In December 2021 the same data reported 73.6% of Delta and 24.5% of Omicron [18]. The results of the COVIDIAG assay confirmed the capacity of immune escape of the Delta and Omicron VOCs with a lower proportion of patients immunized and if is the case in a lower level [19]. This assay was indeed proven to show a strong correlation between specific RBD antibodies titers and live viral neutralization ability of sera [19]. Thus, even if some serological cross-reactivity has been previously described with other serological assays on African samples [16], no such cross-reactivity is expected with the assays used in this study.

A major limitation of this study is that it was not initially designed for an SARS-CoV-2 investigation, which did not allow us to collect specific information about SARS-CoV-2 infection such as clinical manifestations of SARS-CoV-2 or history of screening or hospitalization related to COVID-19.

## Conclusion

This is the first seroprevalence study of SARS-CoV-2 conducted in sub-Saharan Africa among street adolescents in mid-2021. This study showed a very high prevalence with approximately 2/3 of Togolese street adolescents having antibodies to SARS-CoV-2 due to a previous infection. The seroprevalence data from this survey in a population with limited access to the health system and non-compliance with government measures confirm those observed in the general population. These results confirm an under-reporting of COVID-19 cases in Togo, questioning the hypothesis of a low circulation of the virus in Togo and even in Africa.

## Acknowledgements

We are thankful to the members of the NGOs (JADE *pour la Vie*, AGOPODE, and ANGE) who helped to mobilize the street adolescents. We are also thankful to ANRS|MIE for funding the salary of Rodion Konu for his thesis.

## Authors' contributions

AJS and DKE designed the study. AJS, ACD and DKE supervised the study implementation and data collection. VMF, CC and DD performed, verified and supervised biological procedures for SARS-CoV-2 antibodies detection and quantification. Statistical analysis was performed by VMF, AJS and RYK. Data interpretation and first draft of manuscript was done by AJS, RYK, VMF, CC and DKE. Critical revision of the manuscript for important intellectual content was provided by all the coauthors who have read and commented on the original manuscript and all agreed on the version finalized for submission.

## Funding

This study was supported by the Center for Training and Research in Public Health, Lomé, Togo.

## Data availability

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

## Declarations

### Ethics approval and consent to participate

All methods were carried out in accordance with relevant guidelines and regulations. This study has been approved by the National ethic Committee in Togo (No. 012/2020/CBRS). Informed consent was sought from participants through an informational note detailing the objectives of the study and an introductory consent to participate question. Adolescents over 18 years old were asked to sign a consent form. Adolescents under the age of 18 were asked to give their assent to participate in the study, and then a member of the NGO involved in the care of street adolescents was asked to sign a consent form.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

Received: 16 September 2022 / Accepted: 15 March 2023

Published online: 03 April 2023

## References

1. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. Available at: <https://covid19.who.int/>. Accessed May 10, 2022.
2. Bergeri I, Whelan M, Ware H et al. Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020–Oct 2021. medRxiv; 2021. <https://doi.org/10.1101/2021.12.14.21267791>.
3. Ekouevi DK, Gbeasor-Komlanvi F, Malou-Adom V et al. Seroprevalence of SARS-CoV-2 infection in the general population in Togo in 2021 (1.0) [Data set]. Zenodo. 2022; <https://doi.org/10.5281/zenodo.6519821>.
4. Loubiere S, Monfardini E, Allaria C, et al. Seroprevalence of SARS-CoV-2 antibodies among homeless people living rough, in shelters and squats: a large population-based study in France. PLoS ONE. 2021;16(9):e0255498. <https://doi.org/10.1371/journal.pone.0255498>.
5. Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations. Lancet Public Health. 2020;5:e186–7. [https://doi.org/10.1016/S2468-2667\(20\)30053-0](https://doi.org/10.1016/S2468-2667(20)30053-0).
6. Leung CS, Ho MM, Kiss A, et al. Homelessness and the response to emerging Infectious Disease Outbreaks: Lessons from SARS. J Urban Health. 2008;85:402–10. <https://doi.org/10.1007/s11524-008-9270-2>.
7. Culhane DP, Kane V, Johnston M. Homelessness Research: shaping policy and practice, now and into the future. Am J Public Health. 2013;103:181–S182. <https://doi.org/10.2105/AJPH.2013.301728>.

8. World Bank, Data Bank. Country Profile. Available at: <https://cutt.ly/zHBWUXB>. Accessed March 26, 2022
9. République, Togolaise. Direction Générale de la Statistique et de la Comptabilité Nationale du Togo (DGSCN). Résultats définitifs du 4ième Recensement Général de la Population et de l'Habitat (4ième RGPH4). Lomé: DGSCN ; 2010, 66p. Disponible sur : <https://inseed.tg/download/2958/>.
10. République, Togolaise. COVID 19: situation au Togo. Available from: <https://covid19.gouv.tg/situation-au-togo/>. Accessed May 8, 2022.
11. Gillot C, Douxfils J, Cadrobbi J, et al. An original ELISA-Based multiplex method for the simultaneous detection of 5 SARS-CoV-2 IgG antibodies Directed against different antigens. *J Clin Med*. 2020;9(11):3752.
12. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet*. 2021;397(10283):1459–69.
13. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. *JAMA Intern Med*. 2021;181(5):672–9.
14. Fotis C, Meimetis N, Tsolakos N, et al. Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. *Sci Rep*. 2021;11(1):6614.
15. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat Commun*. 2021;12(1):1162. <https://doi.org/10.1038/s41467-021-21444-5>.
16. Woodford J, Sagara I, Dicko A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroassay performance and optimization in a Population with high background reactivity in Mali. *J Infect Dis*. 2021;224(12):2001–9.
17. World Health Organization (WHO)-Africa Centres for Disease Control and Prevention. (Africa CDC) regional SARS-CoV-2 sequencing lab. SARS-CoV-2 genomic Sequencing results for Togo #4. Available at: <https://cutt.ly/THCT-BSo>. Accessed May 10, 2022.
18. World Health Organization (WHO)-Africa Centres for Disease Control and Prevention. (Africa CDC) regional SARS-CoV-2 sequencing lab. SARS-CoV-2 genomic Sequencing results for Togo #7. Available at: <https://cutt.ly/FHCYi7a>. Accessed May 10, 2022.
19. Ferré VM, Lebourgeois S, Chenane HR, et al. Vaccine ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays. *J Infect*. 2022;84(6):834–72.

### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.